$DRIO
DarioHealth Corp.

2022 Q3 Form 10-Q Financial Statement

#000155837022013549 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $6.605M $6.183M $8.059M
YoY Change 17.34% 17.53% 124.17%
Cost Of Revenue $4.805M $3.951M $3.142M
YoY Change 55.15% 30.27% 58.05%
Gross Profit $1.800M $1.138M $3.985M
YoY Change 117.92% -24.54% 268.64%
Gross Profit Margin 27.25% 18.41% 49.45%
Selling, General & Admin $11.57M $14.36M $13.93M
YoY Change -35.07% -8.96% 9.25%
% of Gross Profit 642.78% 1261.51% 349.56%
Research & Development $4.803M $4.137M $5.927M
YoY Change -12.77% 10.56% 123.24%
% of Gross Profit 266.83% 363.53% 148.73%
Depreciation & Amortization $1.226M $1.208M $70.00K
YoY Change -9.79% 51.19% 9.38%
% of Gross Profit 68.11% 106.15% 1.76%
Operating Expenses $16.37M $18.49M $19.86M
YoY Change -29.8% -5.22% 28.87%
Operating Profit -$14.57M -$17.36M -$15.87M
YoY Change -35.23% -3.6% 10.78%
Interest Expense $93.00K $62.00K -$18.00K
YoY Change 57.63% -75.3% -97.0%
% of Operating Profit
Other Income/Expense, Net -$1.059M -$672.0K -$44.00K
YoY Change -2025.45% -382.35% -93.11%
Pretax Income -$15.63M -$18.03M -$15.92M
YoY Change -30.35% 1.47% 6.32%
Income Tax $0.00 $1.000K
% Of Pretax Income
Net Earnings -$15.63M -$18.03M -$15.92M
YoY Change -30.35% 1.48% 6.35%
Net Earnings / Revenue -236.67% -291.57% -197.49%
Basic Earnings Per Share $0.64 $0.74 $0.74
Diluted Earnings Per Share $0.64 $0.74 $0.74
COMMON SHARES
Basic Shares Outstanding 22.98M 22.43M 19.62M
Diluted Shares Outstanding 22.97M 22.43M 19.62M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $57.26M $68.13M $55.75M
YoY Change 11.0% 6.26% -31.51%
Cash & Equivalents $57.08M $67.95M $55.56M
Short-Term Investments $176.0K $177.0K $190.0K
Other Short-Term Assets
YoY Change
Inventory $7.762M $8.347M $7.783M
Prepaid Expenses
Receivables $4.521M $3.138M $4.574M
Other Receivables $2.042M $2.833M $3.271M
Total Short-Term Assets $71.58M $82.44M $71.38M
YoY Change 20.86% 15.13% -19.17%
LONG-TERM ASSETS
Property, Plant & Equipment $858.0K $773.0K $698.0K
YoY Change 20.34% 12.68% -41.83%
Goodwill $41.64M $41.64M $41.64M
YoY Change 5.69% 5.69%
Intangibles $11.05M $12.19M $13.31M
YoY Change -36.51% -34.81%
Long-Term Investments
YoY Change
Other Assets $27.00K $80.00K $23.00K
YoY Change -64.94% -49.04% -88.5%
Total Long-Term Assets $54.75M $54.90M $55.96M
YoY Change -5.53% -7.54% 55.86%
TOTAL ASSETS
Total Short-Term Assets $71.58M $82.44M $71.38M
Total Long-Term Assets $54.75M $54.90M $55.96M
Total Assets $126.3M $137.3M $127.3M
YoY Change 7.81% 4.85% 2.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.982M $3.280M $4.228M
YoY Change -50.33% -18.89% 24.35%
Accrued Expenses $270.0K $137.0K $212.0K
YoY Change -7.85% -55.95% -29.33%
Deferred Revenue $990.0K $999.0K $1.093M
YoY Change -18.38% -23.68%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.52M $12.99M $13.10M
YoY Change -9.12% 1.89% 11.95%
LONG-TERM LIABILITIES
Long-Term Debt $24.05M $23.06M $0.00
YoY Change
Other Long-Term Liabilities $1.818M $1.640M $48.00K
YoY Change 2654.55% 1212.0% -76.0%
Total Long-Term Liabilities $25.86M $24.70M $48.00K
YoY Change 39087.88% 19660.8% -76.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.52M $12.99M $13.10M
Total Long-Term Liabilities $25.86M $24.70M $48.00K
Total Liabilities $37.39M $37.69M $13.15M
YoY Change 193.31% 192.83% 10.47%
SHAREHOLDERS EQUITY
Retained Earnings -$273.0M -$256.8M -$238.4M
YoY Change 36.52% 45.1%
Common Stock $2.000K $2.000K $2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $88.95M $99.65M $114.2M
YoY Change
Total Liabilities & Shareholders Equity $126.3M $137.3M $127.3M
YoY Change 7.81% 4.85% 2.52%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$15.63M -$18.03M -$15.92M
YoY Change -30.35% 1.48% 6.35%
Depreciation, Depletion And Amortization $1.226M $1.208M $70.00K
YoY Change -9.79% 51.19% 9.38%
Cash From Operating Activities -$10.70M -$11.11M -$18.09M
YoY Change -13.99% -9.69% 71.8%
INVESTING ACTIVITIES
Capital Expenditures -$174.0K -$159.0K $66.00K
YoY Change 81.25% 488.89% -2.94%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Cash From Investing Activities -$174.0K -$159.0K -$181.0K
YoY Change 79.38% -96.85% -92.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $38.02M
YoY Change -41.39%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 23.65M 38.02M
YoY Change 42135.71% -42.14%
NET CHANGE
Cash From Operating Activities -10.70M -11.11M -18.09M
Cash From Investing Activities -174.0K -159.0K -181.0K
Cash From Financing Activities 0.000 23.65M 38.02M
Net Change In Cash -10.87M 12.38M 19.75M
YoY Change -13.27% -171.53% -62.48%
FREE CASH FLOW
Cash From Operating Activities -$10.70M -$11.11M -$18.09M
Capital Expenditures -$174.0K -$159.0K $66.00K
Free Cash Flow -$10.52M -$10.96M -$18.16M
YoY Change -14.73% -10.79% 71.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Assets Current
AssetsCurrent
45605000
CY2022Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
9000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
20000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
212000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
287000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16573420
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22860044
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
11927
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10797
us-gaap Revenue Practical Expedient Remaining Performance Obligation
RevenuePracticalExpedientRemainingPerformanceObligation
true
CY2022Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P6M
CY2022Q2 us-gaap Debt Instrument Term
DebtInstrumentTerm
P5Y
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.74
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.85
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22426019
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15691359
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21925089
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15460758
dei Entity Central Index Key
EntityCentralIndexKey
0001533998
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
55166000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37704
dei Entity Registrant Name
EntityRegistrantName
DarioHealth Corp.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2973162
dei Entity Address Address Line1
EntityAddressAddressLine1
18 W. 18th St.
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10011
dei City Area Code
CityAreaCode
972
dei Local Phone Number
LocalPhoneNumber
770-6377
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
DRIO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22979129
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67949000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35808000
CY2022Q2 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
177000
CY2021Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
192000
CY2022Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
3138000
CY2021Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1310000
CY2022Q2 us-gaap Inventory Net
InventoryNet
8347000
CY2021Q4 us-gaap Inventory Net
InventoryNet
6228000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2833000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2067000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
82444000
CY2022Q2 drio Long Term Assets Noncurrent
LongTermAssetsNoncurrent
71000
CY2021Q4 drio Long Term Assets Noncurrent
LongTermAssetsNoncurrent
57000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
773000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
702000
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12190000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12460000
CY2022Q2 us-gaap Goodwill
Goodwill
41640000
CY2021Q4 us-gaap Goodwill
Goodwill
41640000
CY2022Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
54895000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
85549000
CY2022Q2 us-gaap Assets
Assets
137339000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
137339000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
100771000
CY2021Q4 us-gaap Assets
Assets
100771000
CY2022Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
3280000
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6183000
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5261000
drio Amortization Of Acquired Technology
AmortizationOfAcquiredTechnology
2026000
drio Amortization Of Acquired Technology
AmortizationOfAcquiredTechnology
1095000
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
5109000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
999000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1195000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
137000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
266000
CY2022Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
6806000
CY2021Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
7806000
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1764000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
825000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12986000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15201000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
52000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
23061000
CY2022Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1588000
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
24701000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
21000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22860044
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16573420
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10797
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
11927
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
356492000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
307561000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-256842000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222014000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
99652000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14242000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8856000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3951000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3033000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7093000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5172000
CY2022Q2 drio Amortization Of Acquired Technology
AmortizationOfAcquiredTechnology
1094000
CY2021Q2 drio Amortization Of Acquired Technology
AmortizationOfAcquiredTechnology
720000
drio Deemed Dividend
DeemedDividend
-1032000
CY2022Q2 us-gaap Gross Profit
GrossProfit
1138000
CY2021Q2 us-gaap Gross Profit
GrossProfit
1508000
us-gaap Gross Profit
GrossProfit
5123000
us-gaap Gross Profit
GrossProfit
2589000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4137000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3742000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10064000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6397000
CY2022Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
9297000
CY2021Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
9648000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
18832000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
16780000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5059000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6121000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9454000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11742000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
18493000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
19511000
us-gaap Operating Expenses
OperatingExpenses
38350000
us-gaap Operating Expenses
OperatingExpenses
34919000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17355000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18003000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33227000
us-gaap Operating Income Loss
OperatingIncomeLoss
-32330000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-672000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
238000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-716000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-401000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18027000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17765000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33943000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32731000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-18028000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17765000
us-gaap Net Income Loss
NetIncomeLoss
-33944000
us-gaap Net Income Loss
NetIncomeLoss
-32731000
CY2022Q2 drio Deemed Dividend
DeemedDividend
-433000
CY2021Q2 drio Deemed Dividend
DeemedDividend
-488000
drio Deemed Dividend
DeemedDividend
-884000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18461000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18253000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34828000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33763000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.74
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.99
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.43
drio Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-65000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.85
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22426019
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15691359
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21925089
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2119000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-41000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15460758
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
85549000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
161000
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
113000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1301000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3768000
CY2022Q1 drio Issuance Of Common Stock And Prefunded Warrants Net Of Issuance Cost
IssuanceOfCommonStockAndPrefundedWarrantsNetOfIssuanceCost
38023000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15916000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
114185000
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
74000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
557000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2998000
CY2022Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
134000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-18028000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
99652000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28151000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
72000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
201000
CY2021Q1 drio Warrants Issued During Period Exercise Of Warrants Value
WarrantsIssuedDuringPeriodExerciseOfWarrantsValue
633000
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1484000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
846000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2036000
CY2021Q1 drio Stock Issued During Period Value Common Stock
StockIssuedDuringPeriodValueCommonStock
64877000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14966000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
112267000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
27000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55000
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
889000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1951000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2595000
CY2021Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
18094000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17765000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
118113000
us-gaap Profit Loss
ProfitLoss
-33944000
us-gaap Profit Loss
ProfitLoss
-32731000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
8972000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
9900000
us-gaap Depreciation
Depreciation
154000
us-gaap Depreciation
Depreciation
133000
drio Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-75000
drio Amortization Of Inventory Set Up
AmortizationOfInventorySetUp
523000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2087000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1106000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1828000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
452000
drio Increase Decrease In Other Accounts Receivable And Prepaid Expenses And Long Term Assets
IncreaseDecreaseInOtherAccountsReceivableAndPrepaidExpensesAndLongTermAssets
-562000
drio Increase Decrease In Other Accounts Receivable And Prepaid Expenses And Long Term Assets
IncreaseDecreaseInOtherAccountsReceivableAndPrepaidExpensesAndLongTermAssets
134000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1838000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
54000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1107000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1472000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-196000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-43000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-98000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-96000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
939000
drio Non Cash Financial Expenses
NonCashFinancialExpenses
256000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29209000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22838000
drio Payments For Proceeds From Acquire Leases Held For Investment
PaymentsForProceedsFromAcquireLeasesHeldForInvestment
1000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
225000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
97000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
115000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-340000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7593000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
38023000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64877000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
633000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
256000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
23786000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
134000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
61675000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
65766000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
32126000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
35335000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35948000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28725000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68074000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64060000
us-gaap Interest Paid Net
InterestPaidNet
181000
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Operating Income Loss
OperatingIncomeLoss
-33227000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29209000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67949000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
999000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 54pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 54pt;"><span style="font-family:'Helvetica';font-size:8pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">Preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and judgments that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities, which are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. These estimates are based on management's knowledge about current events and expectations about actions we may undertake in the future. Actual results could differ materially from those estimates.</p>
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67949000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63865000
CY2022Q2 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
125000
CY2021Q2 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
195000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68074000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64060000
CY2022Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
50000000
CY2022Q2 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
25000000
CY2022Q2 drio Line Of Credit Amount Available Subject To Revenue Requirements
LineOfCreditAmountAvailableSubjectToRevenueRequirements
25000000
CY2021Q2 drio Business Acquisition Contingent Consideration Shares
BusinessAcquisitionContingentConsiderationShares
237076
CY2022Q3 drio Reduction In Earnout Threshold Of Revenue
ReductionInEarnoutThresholdOfRevenue
5000000
CY2022Q3 drio Reduction In Earnout Threshold Of Revenue
ReductionInEarnoutThresholdOfRevenue
3000000
CY2022Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1222000
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
714000
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7125000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5514000
CY2022Q2 us-gaap Inventory Net
InventoryNet
8347000
CY2021Q4 us-gaap Inventory Net
InventoryNet
6228000
us-gaap Inventory Write Down
InventoryWriteDown
22000
CY2021 us-gaap Inventory Write Down
InventoryWriteDown
73000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1878168
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.13
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M15D
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6183000
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5261000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14242000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8856000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1195000
CY2022Q2 drio New Performance Obligations
NewPerformanceObligations
3187000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
-3383000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
939000
CY2022Q2 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
25000000
CY2022Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1930000
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
226586
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.62
CY2022Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P7Y
CY2022Q2 drio Additional Warrant Outstanding Term
AdditionalWarrantOutstandingTerm
P7Y
CY2022Q2 drio Percentage Of Delayed Draw Commitment Amount
PercentageOfDelayedDrawCommitmentAmount
0.06
CY2022Q2 drio Number Of Days Volume Weighted Average Price
NumberOfDaysVolumeWeightedAveragePrice
10
drio Initial Commitment Amount Remeasurement Income
InitialCommitmentAmountRemeasurementIncome
351000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3861000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
719050
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
78692
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
17.47
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
209098
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.91
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2309428
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.12
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M20D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
253000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2149618
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
15.23
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y4M6D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
245000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
842507
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
20.07
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M14D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
206000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
32966000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M18D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7198771
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8972000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9900000
drio Bank Charges
BankCharges
45000
drio Bank Charges
BankCharges
56000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-138000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-369000
us-gaap Investment Income Interest
InvestmentIncomeInterest
21000
us-gaap Investment Income Interest
InvestmentIncomeInterest
24000
us-gaap Interest Expense Debt
InterestExpenseDebt
181000
drio Revaluation Of Long Term Loan
RevaluationOfLongTermLoan
9000
drio Revaluation Of Warrant Liability
RevaluationOfWarrantLiability
342000
drio Debt Issuance Costs
DebtIssuanceCosts
724000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-716000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-401000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5746978
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31267000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28608000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21925089
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15460758
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.85

Files In Submission

Name View Source Status
0001558370-22-013549-index-headers.html Edgar Link pending
0001558370-22-013549-index.html Edgar Link pending
0001558370-22-013549.txt Edgar Link pending
0001558370-22-013549-xbrl.zip Edgar Link pending
drio-20220630.xsd Edgar Link pending
drio-20220630x10q.htm Edgar Link pending
drio-20220630xex10d1.htm Edgar Link pending
drio-20220630xex10d2.htm Edgar Link pending
drio-20220630xex31d1.htm Edgar Link pending
drio-20220630xex31d2.htm Edgar Link pending
drio-20220630xex32d1.htm Edgar Link pending
drio-20220630xex32d2.htm Edgar Link pending
drio-20220630xex4d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
drio-20220630_lab.xml Edgar Link unprocessable
drio-20220630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
drio-20220630_def.xml Edgar Link unprocessable
drio-20220630x10q_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
drio-20220630_pre.xml Edgar Link unprocessable